NICE TAs

24/07/2020

TA346: Aflibercept for treating diabetic macular oedema

23/07/2020

TA345: Naloxegol for treating opioid‑induced constipation

23/07/2020

TA433: Apremilast for treating active psoriatic arthritis (replaced TA372)

21/07/2020

TA378: Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy

21/07/2020

TA419: Apremilast for treating moderate to severe plaque psoriasis (replaced TA368)

21/07/2020

TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C

21/07/2020

TA350: Secukinumab for treating moderate to severe plaque psoriasis

21/07/2020

TA370: Bortezomib for previously untreated mantle cell lymphoma

21/07/2020

TA369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears

14/07/2020

TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women

10/06/2020

TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab

10/06/2020

TA632: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer

10/06/2020

TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer

10/06/2020

TA624: Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis

29/05/2020

TA379: Nintedanib for treating idiopathic pulmonary fibrosis

29/05/2020

TA620: Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer

29/05/2020

TA356: Ruxolitinib for treating polycythaemia vera (terminated appraisal)

29/05/2020

TA358: Tolvaptan for treating autosomal dominant polycystic kidney disease

22/05/2020

TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer

22/05/2020

TA355: Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation